These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 17107395)
21. [Opinion of Spanish dermatologists regarding the use of biologic therapy in patients with moderate to severe psoriasis]. Ara M; Pérez A; Ferrando J Actas Dermosifiliogr; 2011 Nov; 102(9):706-16. PubMed ID: 21600532 [TBL] [Abstract][Full Text] [Related]
22. Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy. Stine JG; Bass M; Ibrahim D; Khokhar OS; Lewis JH South Med J; 2011 Dec; 104(12):781-8. PubMed ID: 22089354 [TBL] [Abstract][Full Text] [Related]
23. Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups. Kim J; Kim DJ; Ortenzio FS; Dare L; Frank C; Kost RG; Lowes MA JAMA Dermatol; 2016 Jun; 152(6):720-2. PubMed ID: 27028481 [No Abstract] [Full Text] [Related]
24. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. Opmeer BC; Heydendael VM; deBorgie CA; Spuls PI; Bossuyt PM; Bos JD; de Rie MA J Clin Epidemiol; 2007 Jul; 60(7):696-703. PubMed ID: 17573985 [TBL] [Abstract][Full Text] [Related]
25. Drug supply for psoriasis - results from a national pharmacy network. Franzke N; Montenbruck M; Langenbruch AK; Beikert FC; Kresken J; Augustin M J Dtsch Dermatol Ges; 2013 Jul; 11(7):638-43. PubMed ID: 23464851 [TBL] [Abstract][Full Text] [Related]
26. Dermatologists' views and opinions about photo(chemo)therapy and conventional systemic psoriasis therapies: results from a Belgian survey. Nijsten T; Lambert J Dermatology; 2006; 213(2):123-33. PubMed ID: 16902289 [TBL] [Abstract][Full Text] [Related]
27. What do patients and dermatologists prefer regarding low-risk basal cell carcinoma follow-up care? A discrete choice experiment. van Egmond S; de Vries E; Hollestein L; Bastiaens M; de Roos KP; Kuijpers D; Steyerberg E; Wakkee M; Mosterd K; Nijsten T; de Bekker-Grob EW PLoS One; 2021; 16(3):e0249298. PubMed ID: 33780499 [TBL] [Abstract][Full Text] [Related]
28. What is clearance worth? Patients' stated risk tolerance for psoriasis treatments. Fairchild AO; Reed SD; Johnson FR; Anglin G; Wolka AM; Noel RA J Dermatolog Treat; 2017 Dec; 28(8):709-715. PubMed ID: 28494683 [TBL] [Abstract][Full Text] [Related]
29. Translating psoriasis treatment guidelines into clinical practice - the need for educational interventions and strategies for broad dissemination. Nast A; Erdmann R; Pathirana D; Rzany B J Eval Clin Pract; 2008 Oct; 14(5):803-6. PubMed ID: 19018914 [TBL] [Abstract][Full Text] [Related]
30. Considerable variation among Iranian dermatologists in the dosing and monitoring of methotrexate for treating psoriasis. Zargari O; Hejazi S; Shahidi-Dadras M; Younespour S; Robati R; Firooz A; Toosi P; Feldman SR Int J Dermatol; 2014 Mar; 53(3):385-9. PubMed ID: 24134730 [TBL] [Abstract][Full Text] [Related]
31. Treatment of psoriasis with non-registered fumaric acid esters in The Netherlands: a nationwide survey among Dutch dermatologists. Fallah Arani S; Balak DM; Neumann HA; Kuipers MV; Thio HB J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):972-5. PubMed ID: 23822581 [TBL] [Abstract][Full Text] [Related]
32. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience. Lecha M; Mirada A; López S; Artés M; J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284 [TBL] [Abstract][Full Text] [Related]
33. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Kerdel F; Zaiac M Dermatol Ther; 2015; 28(6):390-403. PubMed ID: 26258910 [TBL] [Abstract][Full Text] [Related]
34. Information system technologies' role in augmenting dermatologists' knowledge of prescription medication costs. DeMarco SS; Paul R; Kilpatrick RJ Int J Med Inform; 2015 Dec; 84(12):1076-84. PubMed ID: 26228652 [TBL] [Abstract][Full Text] [Related]
35. Identifying the biologic closest to the ideal to treat chronic plaque psoriasis in different clinical scenarios: using a pilot multi-attribute decision model as a decision-support aid. Guibal F; Iversen L; Puig L; Strohal R; Williams P Curr Med Res Opin; 2009 Dec; 25(12):2835-43. PubMed ID: 19916728 [TBL] [Abstract][Full Text] [Related]
36. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential. AlGhamdi KM; Khurram H; Asiri YA; Mandil A Int J Dermatol; 2011 Sep; 50(9):1094-8. PubMed ID: 22126870 [TBL] [Abstract][Full Text] [Related]
37. Psoriasis treatment in the United States at the end of the 20th century. Pearce DJ; Stealey KH; Balkrishnan R; Fleischer AB; Feldman SR Int J Dermatol; 2006 Apr; 45(4):370-4. PubMed ID: 16650160 [TBL] [Abstract][Full Text] [Related]
38. Dermatologists' Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey. Gooderham M; Papp K; Albrecht L; Grewal P; Gaudreau AJ J Drugs Dermatol; 2021 Feb; 20(2):126-132. PubMed ID: 33538558 [TBL] [Abstract][Full Text] [Related]
39. Support needed to involve psoriasis patients in treatment decisions: survey of dermatologists. Tan J; Stacey D; Barankin B; Bissonnette R; Gulliver W; Lui H; Shear N; Bhatti S J Cutan Med Surg; 2011; 15(4):192-200. PubMed ID: 21781625 [TBL] [Abstract][Full Text] [Related]
40. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. Gyulai R; Bagot M; Griffiths CEM; Luger T; Naldi L; Paul C; Puig L; Kemény L J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):224-231. PubMed ID: 24731093 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]